Perl AE, Larson RA, Podoltsev NA, Strickland S, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022;139:3366-3375.
PMID: 35081255